Change in physical performance indicators of the progenies of rats with experimental preeclampsia in early and late pharmacological correction by GABA derivatives

 The aim of the study was to assess the changes in physical performance parameters in the progeny of rats with experimental preeclampsia (EP) undergoing early and late pharmacological treatment with gamma- aminobutyric acid (GABA) derivatives.

Materials and methods. At the first stage, physical performance of 3- and 18-month old progeny of female rats with EP after early pharmacological treatment (from 40th to 70th day of life) with GABA derivatives, succicard (22mg/kg), salifen (7.5 mg/kg), phenibut (25 mg/kg) and a comparator drug,  pantogam (50 mg), was studied. At the second stage, succicard (44 mg/kg), salifen (15 mg/kg), phenibut (50 mg/kg) or pantogam (100 mg) were intragastrically administered in the progeny of rats with EP for 30 days (from  24th to 25th months of life). The horizontal rope walking test (HRWT), Rotarod performance test, Forced swim test with weight load (FSTwWL) were used in the study.

Results. The HRWT, Rotarod performance rest and FSTwWL showed a decrease in muscle strength, coordination and motor activity, and aerobic and anaerobic endurance in rats with EP aged 3, 18 and 25 months as compared to the values of the animals born to intact rats. Succicard, a GABA-derivative, and pantogam, a comparator drug, were effective both in early and late pharmacological interventions, whereas salifen and phenibut were effective only when administered during puberty. As the offspring of EP rats were aging, their muscle strength, coordination, and motor activity were decreasing, while their aerobic and anaerobic endurance was increasing. 

Conclusion. Physical performance in the progeny of rats with induced EP aged 3, 18 and 25 months tended to decrease. Pharmacological treatment with GABA derivatives in the adolescent period attenuated EP consequences.
When administered in the puberty period, only succicard and the  comparator drug, pantogam, had a therapeutic effect. This fact provides evidence that a succicard-based drug can be developed for preventive  management of preeclampsia consequences. 

1. Phipps E.A., Thadhani R., Benzing T., Karumanchi S.A. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology. 2019; 15 (5): 275–289. DOI: 10.1038/s41581-019-0119-6.

2. Stojanovska V., Scherjon S.A., Plösch T. Preeclampsia as modulator of offspring health. Biology of Reproduction. 2016; 94 (3): 53. DOI: 10.1095/biolreprod.115.135780.

3. Тюренков И.Н., Перфилова В.Н., Карамышева В.И., Попова Т.А., Лебедева С.А., Михайлова Л.И., Жакупова Г.А. Гравидопротекторное действие фенибута при экспериментальной преэклампсии. Экспериментальная и клиническая фармакология. 2014; 77 (11): 6–10.

4. Tyurenkov I.N., Perfilova V.N., Reznikova L.B., Smirnova L.A., Ryabukha A.F., Suchkov E.A., Kuznetsov K.A. GABA derivatives citrocard and salifen reduce the intensity of experimental gestosis. Bulletin of Experimental Biology and Medicine. 2014; 157 (1); 42–44. DOI: 10.1007/s10517-014-2487-z.

5. Багметова В.В., Кривицкая А.Н., Тюренков И.Н., Берестовицкая В.М., Васильева О.С. Влияние фенибута и его соли с янтарной кислотой на устойчивость животных к форсированным динамическим и статическим физическим нагрузкам. Фундаментальные исследования. 2012; 4 (2): 243– 246.

6. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Часть 1. М: Гриф и К, 2012: 944.

7. Каркищенко Н.Н. Биомедицинское (доклиническое) изучение лекарственных средств, влияющих на физическую работоспособность. М: ФМБА России, 2017: 133.

8. Maher G.M., O’Keeffe G.W., Kenny L.C., Kearney P.M., Dinan T.G., Khashan A.S. Hypertensive disorders of pregnancy and risk of neurodevelopmental disorders in the offspring: a systematic review and meta-analysis protocol. British Medical Journal. 2017; 7 (10): e018313. DOI: 10.1136/bmjopen-2017-018313.

9. De Souza Rugolo L.M.S., Bentlin M.R., Trindade C.E. Preeclampsia: early and late neonatal outcomes. Neoreviews. 2012; 13 (9): 532–541. DOI: 10.1542/neo.13-9-e532.

10. Bertagnolli M., Luu T.M., Lewandowski A.J., Leeson P., Nuyt A.M. Preterm birth and hypertension: is there a link? Current Hypertension Reports. 2016; 18 (4): 28. DOI: 10.1007/s11906-016-0637-6.

11. Lin S., Leonard D., Co M.A., Mukhopadhyay D., Giri B., Perger L., Beeram M.R., Kuehl T.J., Uddin M.N. Pre-eclampsia has an adverse impact on maternal and fetal health. Translational Research. 2015; 165 (4): 449–463. DOI: 10.1016/j.trsl.2014.10.006.

12. Бурчинский С.Г. ГАМК-ергические средства в фармакотерапии хронической церебральной ишемии. Международный неврологический журнал. 2015; 1 (71): 101–105. DOI: 10.22141/2224-0713.1.71.2015.78449.

13. Зайцева М.С., Иванов Д.Г., Александровская Н.В. Работоспособность крыс в тесте «Вынужденное плавание с грузом» и причины ее вариабельности. Биомедицина. 2015; 4: 30–42.